Wedbush has assumed coverage of Voyager Therapeutics (NASDAQ:VYGR) with an outperform rating, highlighting the company’s ...

Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after ...

Key Takeaways Wedbush upgraded Snowflake as the analysts predicted that the artificial intelligence software era is ...

Major technology stocks are positioned for a strong year-end rally as artificial intelligence initiatives accelerate and ...

We recently published a list of 15 Trending AI Stocks on Latest News and Ratings. In this article, we are going to take a ...

Wedbush notes that in the past two weeks Kioxia filed for an IPO and SanDisk released its 10-12B, telling investors that data from these ...

The EV maker’s stock gained 3.7% on Friday, leaving the shares ahead nearly 40% for the year and giving it a market value of ...

Tesla’s strategic pivot toward AI and autonomy reinforces its position as a leading disruptive technology company, not merely an automaker, the analysts said. Investors are closely watching regulatory ...

A potential Trump administration may ease regulations for self-driving vehicles, accelerating Tesla's progress ...

Wedbush upgraded Voyager Therapeutics (VYGR) to Outperform from Neutral with a price target of $11, up from $7, after assuming coverage of the name. The firm added the company’s tau antibody for ...

Wedbush has assumed coverage of Voyager Therapeutics (NASDAQ:VYGR) with an outperform rating, highlighting the company’s TRACER platform. The investment firm said it believes TRACER alone should ...